معرفی
Lei Peng is an Associate Research Scientist in the Department of Genetics at Yale University School of Medicine. Their research focuses on advancing cancer immunotherapy, particularly through CRISPR-based genetic screens and engineering of immune cells like CAR-NK and CAR-T cells. Peng has contributed to breakthroughs in viral vaccine development, including Omicron-specific mRNA vaccines and monoclonal antibody generation. Their work integrates cutting-edge gene editing technologies with immunological insights to address challenges in cancer treatment and infectious diseases.
Key collaborations include projects with Paul Renauer and Sidi Chen, targeting genetic checkpoints in NK cells and SARS-CoV-2 variant-specific immunity. Research interests span molecular virology, gene delivery systems (AAV/Sleeping Beauty), and structural biology of antibodies. Peng's studies often bridge basic science with translational applications, aiming to enhance therapeutic efficacy through systems-level approaches.
Publications highlight innovations in CRISPR screens for cancer resistance mechanisms, cryo-EM structural analysis of antiviral antibodies, and multiplexed mRNA vaccine strategies. While no awards are explicitly listed, their contributions to high-impact journals like Nature Biotechnology reflect significant scholarly recognition.
